Evidence map›Paper›PMID 37645223›Full record

ReviewFrontiers in microbiology2023

Novel receptor, mutation, vaccine, and establishment of coping mode for SARS-CoV-2: current status and future.

Zhaomu Zeng, Xiuchao Geng, Xichao Wen, Yueyue Chen, Yixi Zhu, Zishu Dong, Liangchao Hao, Tingting Wang, Jifeng Yang, Ruobing Zhang and 3 more

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Frontiers in microbiology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Review
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Zhaomu Zeng *Department of Neurosurgery, Jiangxi Provincial People's Hospital, The First Affiliated Hospital of Nanchang Medical College, Nanchang, China.
Xiuchao Geng *Department of Nursing, School of Medicine, Taizhou University, Taizhou, China.
Xichao Wen *Department of Neurosurgery, Affiliated Hospital of Hebei University, Baoding, China.
Yueyue ChenDepartment of Toxicology and Sanitary Chemistry, School of Public Health, Capital Medical University, Beijing, China.
Yixi ZhuDepartment of Pharmacy, The Second Affiliated Hospital of Nanchang University, Nanchang, China.
Zishu DongDepartment of Zoology, Advanced Research Institute, Jiangxi University of Chinese Medicine, Nanchang, China.
Liangchao HaoDepartment of Plastic Surgery, Shaoxing People's Hospital, Shaoxing, China.
Tingting WangDepartment of Neurosurgery, Affiliated Hospital of Hebei University, Baoding, China.
Jifeng YangDepartment of Neurosurgery, Affiliated Hospital of Hebei University, Baoding, China.
Ruobing ZhangDepartment of Neurosurgery, Affiliated Hospital of Hebei University, Baoding, China.
Kebin ZhengDepartment of Neurosurgery, Affiliated Hospital of Hebei University, Baoding, China.
Zhiwei SunDepartment of Toxicology and Sanitary Chemistry, School of Public Health, Capital Medical University, Beijing, China.
Yuhao ZhangCancer Center, Department of Neurosurgery, Zhejiang Provincial People's Hospital (Affiliated People's Hospital), Hangzhou Medical College, Hangzhou, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Since the outbreak of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and its resultant pneumonia in December 2019, the cumulative number of infected people worldwide has exceeded 670 million, with over 6.8 million deaths. Despite the marketing of multiple series of vaccines and the implementation of strict prevention and control measures in many countries, the spread and prevalence of SARS-CoV-2 have not been completely and effectively controlled. The latest research shows that in addition to angiotensin converting enzyme II (ACE2), dozens of protein molecules, including AXL, can act as host receptors for SARS-CoV-2 infecting human cells, and virus mutation and immune evasion never seem to stop. To sum up, this review summarizes and organizes the latest relevant literature, comprehensively reviews the genome characteristics of SARS-CoV-2 as well as receptor-based pathogenesis (including ACE2 and other new receptors), mutation and immune evasion, vaccine development and other aspects, and proposes a series of prevention and treatment opinions. It is expected to provide a theoretical basis for an in-depth understanding of the pathogenic mechanism of SARS-CoV-2 along with a research basis and new ideas for the diagnosis and classification, of COVID-19-related disease and for drug and vaccine research and development.

Indexed as

attachment factorsCOVID-19 vaccinesentry receptorsheterologous booster immunizationOmicron variantsmall molecule antiviral drugs

Identifiers

PMID37645223
PMCPMC10461067

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.